Groupe d'Etude en Oncologie du Quebec

Title	This is a single-center randomized trial in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibition. Patients will receive standard-of-care immune checkpoint inhibitor (ICI) therapy alone or in combination with a dietary intervention
Protocole ID	2023-11332
ClinicalTrials.gov ID	NCT05805319
Cancer Type(s)	Non Small Cells - Lung
Phase	Other
Stage
Study Type	Support
Drug	Intervention concernant la diète alimentaire
Institution	CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
City
Principal Investigator	Dr. Bertrand Routy
Coordinator	Wiam Belkaid 514-890-8000
Status	Recruiting
Activation Date	07-05-2024
Eligibility Criteria	Signed, informed consent Age 18 years or older Confirmed histological diagnosis of non-small cell lung cancer (NSCLC); Treatment with standard-of-care ICI Ability to eat solid foods
Exclusion Criteria	Severe dietary allergies (e.g. shellfish, nuts, seafood) Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

Groupe d'étude en oncologie du Québec